Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study evaluate the efficacy of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase inhibitors, also known as \"statins\" in the treatment of growth and skeletal abnormalities in children with Noonan syndrome. Half of patients will receive simvastatin while the other half will receive a placebo.
Epistemonikos ID: 71fc9f64ae2f08007acafc6ed1a54e7309343000
First added on: May 12, 2024